Next Article in Journal
A Quantitative Curriculum Mapping of the Faculty of Pharmacy of Yeditepe University, Turkey: A Process to Assess the Consistency of a Curriculum with the Mission and Vision of an Institution and National Requirements
Next Article in Special Issue
The Basics of Penicillin Allergy: What A Clinician Should Know
Previous Article in Journal
Pilot and Feasibility of Combining a Medication Adherence Intervention and Group Diabetes Education for Patients with Type-2 Diabetes
Previous Article in Special Issue
Strategies for Clarifying Penicillin Allergies When Skin Testing Is Not an Option
Article Menu

Export Article

An updated version is available. Download PDF

Open AccessReview

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors

Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, MS 39216, USA
*
Author to whom correspondence should be addressed.
Pharmacy 2019, 7(3), 77; https://doi.org/10.3390/pharmacy7030077
Received: 11 June 2019 / Revised: 24 June 2019 / Accepted: 25 June 2019 / Published: 28 June 2019
(This article belongs to the Special Issue Antibiotic Allergies)
  |  
PDF [335 KB, uploaded 16 July 2019]
  |     |  

Abstract

Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-lactamase inhibitors. Clavulanate, sulbactam, and tazobactam are beta-lactam-based beta-lactamase inhibitors that are combined with several penicillins or cephalosporins in order to preserve antimicrobial activity in the presence of beta-lactamases. Avibactam, relebactam, and vaborbactam are non-beta-lactam beta-lactamase inhibitors that are combined with cephalosporins or carbapenems in order to expand the antimicrobial activity against broader-spectrum beta-lactamases. Case reports document hypersensitivity reactions to clavulanate, sulbactam, and tazobactam, but not to avibactam, relebactam, or vaborbactam. Based on these reports and considering the chemical structures, cross-allergenicity with beta-lactams is likely with sulbactam and tazobactam. Considering the slightly altered beta-lactam structure, cross-allergenicity is less likely with clavulanate, but still possible. It appears that cross-allergenicity between beta-lactam antimicrobials and the newer, non-beta-lactam beta-lactamase inhibitors is unlikely. It is important for clinicians to perform allergy testing to both the beta-lactam and the beta-lactamase inhibitor in order to confirm the specific allergy and reaction type. View Full-Text
Keywords: beta-lactam allergy; clavulanate; sulbactam; tazobactam; avibactam; relebactam; vaborbactam; cross reactivity; hypersensitivity beta-lactam allergy; clavulanate; sulbactam; tazobactam; avibactam; relebactam; vaborbactam; cross reactivity; hypersensitivity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Stover, K.R.; Barber, K.E.; Wagner, J.L. Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors. Pharmacy 2019, 7, 77.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmacy EISSN 2226-4787 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top